Predictors of Avascular Necrosis after Kidney Transplantation

Ko, Young Min; Kwon, Hyunwook; Chun, Sung; Kim, Young Hoon; Choi, Ji Yoon; Shin, Sung; Jung, Joohee; Park, Su-Kil; Han, Duck Jong

doi:10.4285/jkstn.2017.31.4.200

Cited by 1 publication

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For liver transplant recipients, the target trough concentration of tacrolimus was 10–15 ng/ml for the first month, 8–10 ng/ml within the first year, 5–8 ng/ml at 1–3 years, 5 ng/ml at 3–5 years, 3–5 ng/ml at 6–10 years, and 2–3 ng/ml after 10 years 24,25 . For kidney transplant recipients, the target trough level for tacrolimus was 6–8 ng/ml during the early postoperative period and was decreased to 3–6 ng/ml after 1 year 26,27 . For heart or lung transplant recipients, tacrolimus was adjusted to a target trough level of 10–15 ng/ml for the initial 6 months after transplantation and 8–12 ng/ml thereafter 28 …”

Section: Methodsmentioning

confidence: 99%

“…24,25 For kidney transplant recipients, the target trough level for tacrolimus was 6-8 ng/ml during the early postoperative period and was decreased to 3-6 ng/ml after 1 year. 26,27 For heart or lung transplant recipients, tacrolimus was adjusted to a target trough level of 10-15 ng/ml for the initial 6 months after transplantation and 8-12 ng/ml thereafter. 28…”

Section: Institutional Protocol For Target Tacrolimus Drug-level Adju...mentioning

confidence: 99%

See 1 more Smart Citation

Drug‐level change and optimal dose adjustment of tacrolimus with the use of rifabutin for treating mycobacterial disease in solid organ transplant recipients

Kim

Shim

2022

Transplant Infectious Dis

View full text Add to dashboard Cite

Background:Little is known about the change in drug level and the need for dose adjustment of calcineurin inhibitor when it is used with rifabutin in solid organ transplant (SOT) recipients. We aimed to analyze whether the drug level of tacrolimus significantly reduced after the use of rifabutin and to assess optimal adjustment of tacrolimus dose in SOT recipients.Methods: Of the SOT recipients in a tertiary referral center in South Korea in 2000-2019, 50 patients who maintained an unchanged dose of tacrolimus after the use of rifabutin for treating mycobacterial disease were enrolled. Their medical records were reviewed retrospectively. Results:The mean age of the patients was 53.9 ± 11.5 years. The most commonly transplanted organ was the liver (66.0%). The most common indication of rifabutin use was for treating active tuberculosis (78.0%). After rifabutin initiation, the trough level of tacrolimus decreased significantly to the subtherapeutic range in 38 (76.0%) patients.The drug levels of these 38 patients dropped from 7.2 to 3.8 ng/ml (p < .001) after rifabutin treatment. In these patients, the median 1.5-fold increase in the tacrolimus dose was required to restore the drug level to the within-therapeutic range. Conclusions:These findings indicate that careful tacrolimus drug-level monitoring and dose adjustment are necessary for most SOT recipients when rifabutin is administered for the treatment of mycobacterial disease.

show abstract

Section: Methodsmentioning

confidence: 99%